| 1. |
- Bashir, Amna, et al.
(författare)
-
Cu-doped nickel oxide interface layer with nanoscale thickness for efficient and highly stable printable carbon-based perovskite solar cell
- 2019
-
Ingår i: Solar Energy. - : PERGAMON-ELSEVIER SCIENCE LTD. - 0038-092X .- 1471-1257. ; 182, s. 225-236
-
Tidskriftsartikel (refereegranskat)abstract
- The power conversion efficiency (PCE) of hole conductor free carbon-based perovskite solar cells (PSCs) is restricted by the poor charge extraction and recombination losses at the carbon-perovskite interface. For the first time we successfully demonstrated incorporation of thin layer of copper doped nickel oxide (Cu:NiOx) nanoparticles in carbon-based PSCs, which helps in improving the performance of these solar devices. Cu:NiOx nanoparticles have been synthesized by a facile chemical method, and processed into a paste for screen printing. Extensive X-ray Absorption Spectroscopy (XAS) analysis elucidates the co-ordination of Cu in a NiOx matrix and indicates the presence of around 5.4% Cu in the sample. We fabricated a monolithic perovskite module on a 100 cm(2) glass substrate (active area of 70 cm(2)) with a thin Cu:NiOx layer (80 nm), where the champion device shows an appreciated power conversion efficiency of 12.1% under an AM 1.5G illumination. To the best of our knowledge, this is the highest reported efficiency for such a large area perovskite solar device. I-V scans show that the introduction of Cu:NiOx mesoporous scaffold increases the photocurrent, and yields fill factor (FF) values exceeding 57% due to the better interface and increased hole extraction efficiency. Electrochemical Impedance Spectroscopy (EIS) results reinforce the above results by showing the reduction in recombination resistance (R-rec) of the PSCs that incorporates Cu:NiOx interlayer. The perovskite solar modules with a Cu:NiOx layer are stable for more than 4500 h in an ambient environment (25 degrees C and 65% RH), with PCE degradation of less than 5% of the initial value.
|
|
| 2. |
|
|
| 3. |
- Sood, Mohit, et al.
(författare)
-
Low temperature (Zn,Sn)O deposition for reducing interface open-circuit voltage deficit to achieve highly efficient Se-free Cu(In,Ga)S2 solar cells
- 2022
-
Ingår i: Faraday discussions. - : Royal Society of Chemistry. - 1359-6640 .- 1364-5498. ; 239, s. 328-338
-
Tidskriftsartikel (refereegranskat)abstract
- Cu(In,Ga)S-2 holds the potential to become a prime candidate for use as the top cell in tandem solar cells owing to its tunable bandgap from 1.55 eV (CuInS2) to 2.50 eV (CuGaS2) and favorable electronic properties. Devices above 14% power conversion efficiency (PCE) can be achieved by replacing the CdS buffer layer with a (Zn,Mg)O or Zn(O,S) buffer layer. However, the maximum achievable PCE of these devices is limited by the necessary high heating temperatures during or after buffer deposition, as this leads to a drop in the quasi-Fermi level splitting (qFLs) and therefore the maximum achievable open-circuit voltage (V-OC). In this work, a low-temperature atomic layer deposited (Zn,Sn)O thin film is explored as a buffer layer to mitigate the drop in the qFLs. The devices made with (Zn,Sn)O buffer layers are characterized by calibrated photoluminescence and current-voltage measurements to analyze the optoelectronic and electrical characteristics. An improvement in the qFLs after buffer deposition is observed for devices prepared with the (Zn,Sn)O buffer deposited at 120 degrees C. Consequently, a device with a V-OC value above 1 V was achieved. A 14% PCE is externally measured and certified for the best solar cell. The results show the necessity of developing a low-temperature buffer deposition process to maintain and translate absorber qFLs to device V-OC.
|
|
| 4. |
- Suryawanshi, Rahul K., et al.
(författare)
-
Enhancement of antiviral drug efficacy through multimodal mechanism of Au nanoparticles decorated ZnO tetrapods
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Nanoparticles have been well studied for controlling viral infections. However, very little knowledge exists on their potential use as an adjuvant for enhancing antiviral drug efficacy and reducing toxicity. Herein, we describe gold nanoparticle decorated zinc oxide tetrapods (ANZOT) that electrostatically neutralize viral infections. Given their negative charge distribution caused by engineered oxygen vacancies, ANZOT can prevent herpes simplex virus-1 and the novel human coronavirus, SARS-CoV-2 from infecting cells. More notably, when ANZOT was used as an adjuvant, several fold lower than normally used concentrations of a nucleoside analog, acyclovir or a preclinical antiviral compound, BX795, were enough to inhibit infection and eliminate drug toxicity. BX795 was found to exert its antiviral benefits through inhibition of cellular protein kinase C (α and ζ). Cumulatively our findings highlight an innovative use of ANZOT as a drug adjuvant for superior broad-spectrum effects against viral infections.
|
|
| 5. |
- Suryawanshi, Rahul K., et al.
(författare)
-
Putative targeting by BX795 causes decrease in protein kinase C protein levels and inhibition of HSV1 infection
- 2022
-
Ingår i: Antiviral Research. - : Elsevier. - 0166-3542 .- 1872-9096. ; 208
-
Tidskriftsartikel (refereegranskat)abstract
- Herpes simplex virus type-1 (HSV1) exploits cellular machinery for its own replicative advantage. Current treatment modalities against HSV1 cause toxicity and drug resistance issues. In the search for alternative forms of treatment, we have uncovered a small molecule, BX795, as a candidate drug with strong antiviral potential owing to its multitargeted mode of action. In this study, we show that in addition to a previously known mechanism of action, BX795 can directly interact with the proviral host factor protein kinase C (PKC) in silico. When administered to HSV1 or mock infected human corneal epithelial (HCE) cells, BX795 significantly reduces the protein level and perinuclear localization of proviral PKC-alpha and PKC-zeta isoforms. This activity closely mimics that of a known PKC inhibitor, Bisindolylmaleimide I (BIM I), which also inhibits viral replication. Taken together our studies demonstrate a previously unknown mechanism by which BX795 exerts its antiviral potential.
|
|
